Expand edifying RNAi therapy for mass diseases, Nordisk partners

RNA interference is a biological process in which certain RNA molecules inhibit the expression of disease-causing genes by degrading mRNAsInstead of inhibiting its activity by targeting and binding proteins, RNAi takes effect earlier by targeting and silencing mRNAs that guide protein constructionThis role of RNAi gives it the ability to attack any target, including disease-causing genes that conventional antibodies and small molecule drugs cannot touchIn addition, RNAi therapy can reduce the frequency of administration, extend the duration of action, and facilitate patientsGalXC RNAi technology platform developed by Dicerna aims to promote the development of the next generation of RNAi therapies to silence disease-causing genes in the liver and other tissuesGalXC therapy is treated with Dicer enzymes, which are RNAi's natural starting point in human cellsDicerna's researchers used GalXC to connect N-acetyl semi-lactose sugar directly to small interference RNA (DsiRNA) molecules that can only be cut by Dicer enzymes, which stabilize the RNAi twins while being flexibly and effectively coupled toward the target ingestDicerna believes that this chemical modification can deliver RNAi therapy to the liver by subcutaneous injection and then bind specifically to the receptors on the target cells to promote the absorption of RNAi therapyBy using Dicer enzymeas as RNAi's cutting enzyme, optimize the activity of the RNAi pathway to operate in the most specific and efficient way's RNAi Therapy Design (Photo: Dicerna)under the terms of the agreement, Dicerna will be responsible for the preclinical development of each candidate drug, Novo Nordisk will be responsible for the further development of the selected candidate drug, and both parties will be eligible for commercial development of the drug being developedDicerna will receive an advance of $175 million and a $50 million equity investmentIn addition, Dicerna will be eligible for an additional $75 million in payments over the first three years, as well as a potential milestone payment of $357.5 million for each developed drug and a share of future sales if it completes the development of the planned RNAi therapy"We are pleased to be able to extend the treatment of the GalXC platform to a wide range of liver cell targets and increase our opportunities for development in the field of severe liver disease treatment," said DrDouglas MFambrough, President and CEO of Dicerna"Novo Nord's expertise in cardiovascular disease and years of experience in developing and commercializing innovative therapies around the world will help us develop new RNAi treatments for the benefit of a wide range of patients who do not meet treatment needs." "
" Dicerna developed RNAi therapies that can develop a variety of potential treatments in areas such as diabetes, obesity, cardiovascular disease and NASH," said Marcus Schindler, senior vice president of global drug development at Novo Nordisk References: sirna and Novo Nordisk Enter Agreement to Discover and Develop RNAi Therapies for Related Cardio-Jari Diseases, Retrieved November 18, 2019, from https://